You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’

Article info

Article menu
Download PDFPDF
Correspondence
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’

Authors

  • Timm H Westhoff Medical Department I, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Felix S Seibert Medical Department I, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Moritz Anft Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Arturo Blazquez-Navarro Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Berlin Center for Advanced Therapies (BeCAT), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Sarah Skrzypczyk Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Adrian Doevelaar Medical Department I, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Bodo Hölzer Medical Department I, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Krystallenia Paniskaki Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • Sebastian Dolff Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • Benjamin Wilde Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • Oliver Witzke Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • Juergen Braun Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum, Herne, Germany PubMed articlesGoogle scholar articles
  • Ulrik Stervbo Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Berlin Center for Advanced Therapies (BeCAT), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Nina Babel Immundiagnostik, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Center for Translational Medicine, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany Berlin Center for Advanced Therapies (BeCAT), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Nina Babel, Center for Translational Medicine and Diagnostic Immunology, Marien Hospital Herne - University Hospital of the Ruhr-University Bochum, Herne, Germany; nina.babel{at}elisabethgruppe.de
View Full Text

Citation

Westhoff TH, Seibert FS, Anft M, et al
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
Annals of the Rheumatic Diseases 2021;80:e162.

Publication history

  • Received May 10, 2021
  • Accepted May 11, 2021
  • First published July 16, 2021.
Online issue publication 
January 10, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage